Neurohumoral activity, heart failure and prognosis in patients with end-stage renal disease treated by hemodialysis

Kidney and Blood Pressure Research

Volumn 30, Issue 5, 2007, Pages 347-357

  Spinar, J ^a   Ludka, O ^a   Dusek, L ^b   Vitovcova, L ^c   Sobotova, D ^c   Spinarova, L ^c   Tomandl, J ^b   Vitovec, J ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

End stage renal disease; Heart failure; Hemodialysis; Neurohumoral activity

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; URIC ACID;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEMODIALYSIS; HORMONE ACTION; HUMAN; INCIDENCE; KIDNEY FAILURE; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; THORAX RADIOGRAPHY;

ADULT; AGED; ENDOTHELINS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PROGNOSIS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 34748917636     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107797     Document Type: Article

References (30)

1. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A, et al: N-terminalpro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-2174.
2. Cowie MR, Mosterd A, Wood DA, Deckers SW, Poole-Wilson PA, Sutton GC, et al: The epidemiology of heart failure. Eur Heart J 1997;18:208-225.
3. McMurray J, Hart W, Rhodes G: An evaluation of the economic costs of heart failure to the National Health Service in the United Kingdom. Br J Med Econ 1993;6:99-100.
4. Parfrey PS: Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000;15(suppl 5):58-68.
5. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, et al: Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000;15(suppl 5):69-80.
6. Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI, et al: Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000;139:72-77.
7. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL: Heart failure as a cause for hospitalization in chronic dialysis patient. Am J Kidney Dis 2003;41:1267-1277.
8. Spinar J, Vitovec J, Spac J, Blaha M, Spinarova L, Toman J: Non-invasive prognostic factors in chronic heart failure. One year survival of 300 patients with diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. Int J Cardiol 1996;56:283-288.
9. Nieminen MS, Boehm M, Cowie MR, Drexler H, Filippatos GS, Sondeau G, et al: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26:383-416.
10. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:1115-1140.
11. Hunt PJ, Richards AM, Nichols MG, Yandle TG, Doughty RN, Espiner EA, et al: Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-296.
12. Stanton E, Hansen M, Wijeysundera HC, Kupchak P, Hall C, Rouleau SL, et al: A direct comparison of the natriuretic peptides and the relationship to survival in chronic heart failure of a presumed non-ischemic origin. Eur J Heart Fail 2005;7:557-565.
13. Hulsmann M, Berger R, Moertel D, Gore O, Meyer B, Pacher R: Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: a direct comparison of N-terminal atrial natriuretic peptide and brain natriuretic peptide. Eur J Heart Fail 2005;7:552-556.
14. Januzzi LJ, Camargo CA, Anwaruddin, Baggish AL, Chen AA, Krauser DG, et al: The N-terminal pro-BNP investigation of dyspnoe in the emergency department (PRIDE) study. J Am Coll Cardiol 2005;95:948-954.
15. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al: Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-2017.
16. Deedwania PC: Endothelin, the bad actor in the play: a marker or mediator of cardiovascular disease. J Am Coll Cardiol 1999;33:939-942.
17. Kos T, Pacher R, Wimmer A, Bojic A, Hulsmann M, Frey B, et al: Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Wien Klin Wochenschr 1998;110:89-95.
18. 1, dobutamine and placebo on hemodynamic and neurohumoral variables in patients with advanced heart failure. Jpn Heart J 1999;40:321-334.
19. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, et al: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641.
20. Metz CE: ROC methodology in radiologic imaging. Invest Radiol 1986;21:720-733.
21. Altman DG:. Practical Statistics for Medical Research. London, Chapman & Hall 1991, p 619.
22. Zar JH: Biostatistical Methods, ed 2. London, Prentice-Hall 1984, p 556.
23. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al: B-type natriuretic peptide and renal function in the diagnosing of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-579.
24. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implication of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
25. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnet JC Jr, Francis GS, et al: BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congestive Heart Failure 2004;10(suppl 3):1-30.
26. National Kidney Foundation: Clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. Am J Kidney Dis 2002(suppl 1):46-75.
27. Ludka O, Špinar J, Vítovec J, Tomandl J: Neurohumoral activation and heart failure incidence in patients in chronic dialysis programme. 10th Alpe Adria Cardiology Meeting, Vienna, April 17-20, 2002, p 69.
28. Lee SW, Song JH, Kim GA, Lim HJ, Kim MJ: Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patients. Am J Kidney Dis 2003;41:1257-1266.
29. Lee S, Park SK, Kang KP, Kang SK, Kim SZ, Kim W: Relationship of plasma Dendroaspis natriuretic peptide-like immunoreactivity and echocardiographic parameters in chronic haemodialysis patients. Nephrology 2004;9:171-175.
30. Safley DM, Awad A, Sullivan RA, Sandberg KR, Mourad I, Boulware WM, et al: Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis 2005;12:117-124.